Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

Neuroendocrine tumors have demonstrated an increase in incidence ... option for patients with high tumor content of somatostatin type 2 receptors and will be further developed in the future.

The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic ...

Furthermore, the researchers used univariate and multivariate analyses to show that FDG-PET could be used to predict survival in patients with neuroendocrine tumors. “As a rare type of cancer it ...

Monte Rosa Therapeutics’ plan to develop a molecular glue degrader in a wide range of cancers has come unstuck. | Monte Rosa ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new ...